암 생물학적 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Cancer Biological Therapy Market size is expected to reach USD 240.23 Billion in 2034 from USD 146.11 Billion (2025) growing at a CAGR of 5.68% during 2026-2034.

The Global Cancer Biological Therapy Market is expanding rapidly due to the increasing prevalence of cancer worldwide. Biological therapies, including immunotherapy, monoclonal antibodies, and targeted therapies, are becoming key treatment options. These therapies help the body's immune system fight cancer more effectively compared to traditional chemotherapy. Rising awareness about advanced cancer treatments and improved diagnostic technologies are driving the growth of this market.

Key growth drivers include continuous research and development in oncology, government funding, and growing clinical trials for innovative biologic drugs. Pharmaceutical companies are investing heavily in developing targeted therapies with fewer side effects. The aging global population and lifestyle-related cancer cases are also increasing demand for effective treatment options. Additionally, advancements in personalized medicine are improving treatment outcomes and boosting patient confidence.

In the future, the market is expected to witness strong growth with the introduction of next-generation immunotherapies and combination treatment approaches. Expanding healthcare infrastructure in developing countries will further increase accessibility to advanced cancer treatments. As biotechnology continues to evolve and regulatory approvals become faster, the cancer biological therapy market is likely to offer significant growth opportunities worldwide.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type of Therapy

• Monoclonal Antibodies
• Vaccines
• Cytokines
• Gene Therapy

By Cancer Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer

By Administration Route

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

By End User

• Hospitals
• Cancer Research Institutes
• Pharmaceutical Companies

COMPANIES PROFILED

• BristolMyers Squibb, Sanofi, Eli Lilly, Regeneron Pharmaceuticals, Celgene, AbbVie, Gilead Sciences, Amgen, Intuitive Surgical, Johnson and Johnson, Pfizer, Merck, Roche, AstraZeneca, Novartis
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER BIOLOGICAL THERAPY MARKET: BY TYPE OF THERAPY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type Of Therapy
• 4.2. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Cytokines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER BIOLOGICAL THERAPY MARKET: BY CANCER TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Cancer Type
• 5.2. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER BIOLOGICAL THERAPY MARKET: BY ADMINISTRATION ROUTE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Administration Route
• 6.2. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Intramuscular Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANCER BIOLOGICAL THERAPY MARKET: BY END USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End User
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Cancer Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CANCER BIOLOGICAL THERAPY MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Type Of Therapy
  • 8.2.2 By Cancer Type
  • 8.2.3 By Administration Route
  • 8.2.4 By End User
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Type Of Therapy
  • 8.3.2 By Cancer Type
  • 8.3.3 By Administration Route
  • 8.3.4 By End User
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Type Of Therapy
  • 8.4.2 By Cancer Type
  • 8.4.3 By Administration Route
  • 8.4.4 By End User
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Type Of Therapy
  • 8.5.2 By Cancer Type
  • 8.5.3 By Administration Route
  • 8.5.4 By End User
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Type Of Therapy
  • 8.6.2 By Cancer Type
  • 8.6.3 By Administration Route
  • 8.6.4 By End User
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL CANCER BIOLOGICAL THERAPY INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Bristol-Myers Squibb
  • 10.2.2 Sanofi
  • 10.2.3 Eli Lilly
  • 10.2.4 Regeneron Pharmaceuticals
  • 10.2.5 Celgene
  • 10.2.6 AbbVie
  • 10.2.7 Gilead Sciences
  • 10.2.8 Amgen
  • 10.2.9 Intuitive Surgical
  • 10.2.10 Johnson And Johnson
  • 10.2.11 Pfizer
  • 10.2.12 Merck
  • 10.2.13 Roche
  • 10.2.14 AstraZeneca
  • 10.2.15 Novartis